Intensity Therapeutics Inc (INTS) Stock Analysis
Verdict: AVOID
High-conviction clinical data is eclipsed by a 15-month liquidity runway, making INTS a binary bet on partnership milestones or dilution.
Investment score: 38/100
Analysis as of
Is Intensity Therapeutics Inc stock worth reviewing? AI model thesis
INTS is a high-risk, pre-revenue biotech with promising assets but a dangerously thin margin for error regarding its cash position.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Intensity Therapeutics Inc opportunities and risks
What speaks for INTS
- Strategic Collaborations with Merck and BMS
What speaks against INTS
- Liquidity and Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| INTS | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -97.4% |
| JSPR | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -933.2% |
| APUS | n/a | 0.0x | n/a | 0.0% | 0.0% | -993.1% |
| MBRX | n/a | 0.0x | n/a | 0.0% | 0.0% | -193.6% |
| AKTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -86.1% |
| LIANY | 2.5x | 0.0x | n/a | 0.0% | 0.0% | 40.9% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -193.6% |
Frequently asked questions about Intensity Therapeutics Inc (INTS)
Is INTS stock a good investment?
The cached TradeMates AI model rates Intensity Therapeutics Inc as AVOID with an investment score of 38/100. INTS is a high-risk, pre-revenue biotech with promising assets but a dangerously thin margin for error regarding its cash position. This is algorithmic model output, not personal investment advice.
Is INTS stock a buy?
The TradeMates model verdict for INTS is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.